107 related articles for article (PubMed ID: 12218107)
21. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope.
Ryan CM; Schell TD
J Immunol; 2006 Jul; 177(1):255-67. PubMed ID: 16785521
[TBL] [Abstract][Full Text] [Related]
22. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
[TBL] [Abstract][Full Text] [Related]
23. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
24. The role of T cell antagonism and original antigenic sin in genetic immunization.
Singh RA; Rodgers JR; Barry MA
J Immunol; 2002 Dec; 169(12):6779-86. PubMed ID: 12471109
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the HLA-Cw3-specific cytotoxic T lymphocyte response of HLA-B7 X human beta 2m double transgenic mice.
Barra C; Pérarnau B; Gerlinger P; Lemeur M; Gillet A; Gibier P; Lemonnier FA
J Immunol; 1989 Nov; 143(10):3117-24. PubMed ID: 2478616
[TBL] [Abstract][Full Text] [Related]
26. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
[TBL] [Abstract][Full Text] [Related]
27. Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes.
Eggert AO; Andersen MH; Voigt H; Schrama D; Kämpgen E; Straten PT; Becker JC
Eur J Immunol; 2004 Nov; 34(11):3285-90. PubMed ID: 15384049
[TBL] [Abstract][Full Text] [Related]
28. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
29. Design of immunogenic and effective multi-epitope DNA vaccines for melanoma.
Cho HI; Celis E
Cancer Immunol Immunother; 2012 Mar; 61(3):343-51. PubMed ID: 21915800
[TBL] [Abstract][Full Text] [Related]
30. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
[TBL] [Abstract][Full Text] [Related]
31. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters.
Sherritt M; Cooper L; Moss DJ; Kienzle N; Altman J; Khanna R
Int Immunol; 2001 Mar; 13(3):265-71. PubMed ID: 11222495
[TBL] [Abstract][Full Text] [Related]
32. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.
Valmori D; Dutoit V; Schnuriger V; Quiquerez AL; Pittet MJ; Guillaume P; Rubio-Godoy V; Walker PR; Rimoldi D; Liénard D; Cerottini JC; Romero P; Dietrich PY
J Immunol; 2002 Apr; 168(8):4231-40. PubMed ID: 11937585
[TBL] [Abstract][Full Text] [Related]
33. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.
Kobayashi H; Lu J; Celis E
Cancer Res; 2001 Oct; 61(20):7577-84. PubMed ID: 11606397
[TBL] [Abstract][Full Text] [Related]
34. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
[TBL] [Abstract][Full Text] [Related]
35. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein.
Zhang M; Ishii K; Hisaeda H; Murata S; Chiba T; Tanaka K; Li Y; Obata C; Furue M; Himeno K
Immunology; 2004 Aug; 112(4):567-74. PubMed ID: 15270727
[TBL] [Abstract][Full Text] [Related]
36. Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza A viruses.
Belz GT; Stevenson PG; Doherty PC
J Immunol; 2000 Sep; 165(5):2404-9. PubMed ID: 10946264
[TBL] [Abstract][Full Text] [Related]
37. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
Schirmbeck R; Böhm W; Reimann J
J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
[TBL] [Abstract][Full Text] [Related]
38. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.
Thomson SA; Sherritt MA; Medveczky J; Elliott SL; Moss DJ; Fernando GJ; Brown LE; Suhrbier A
J Immunol; 1998 Feb; 160(4):1717-23. PubMed ID: 9469429
[TBL] [Abstract][Full Text] [Related]
39. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
40. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]